221 related articles for article (PubMed ID: 21883828)
21. Mortality and cancer incidence following radiotherapy for seminoma of the testis.
Horwich A; Bell J
Radiother Oncol; 1994 Mar; 30(3):193-8. PubMed ID: 8209001
[TBL] [Abstract][Full Text] [Related]
22. [Risk of second non-germ cell cancer after treatment of stage I-II testicular seminoma].
Bachaud JM; Berthier F; Soulié M; Malavaud B; Plante P; Rischmann P; Chevreau C; Grosclaude P
Prog Urol; 1999 Sep; 9(4):689-95. PubMed ID: 10555222
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of stage I seminoma.
Yang GY; Li B; Wagner TD; Donohue KA; Flaherty L; Kuettel MR
Am J Clin Oncol; 2007 Apr; 30(2):205-10. PubMed ID: 17414472
[TBL] [Abstract][Full Text] [Related]
24. Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: a population-based analysis.
Ahmed KA; Wilder RB
Cancer Epidemiol; 2014 Apr; 38(2):124-8. PubMed ID: 24613492
[TBL] [Abstract][Full Text] [Related]
25. Late recurrence of clinical stage I seminoma of the testis after 12 years despite adjuvant infradiaphragmatic irradiation.
Tavolini IM; Mazzariol C; Dal Bianco M; Bassi P
Urol Int; 2004; 73(1):84-6. PubMed ID: 15263799
[TBL] [Abstract][Full Text] [Related]
26. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma.
Zwahlen DR; Martin JM; Millar JL; Schneider U
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):853-8. PubMed ID: 18164856
[TBL] [Abstract][Full Text] [Related]
27. [Does radiotherapy still have a place in the treatment of stage I seminoma?].
Paule B
Prog Urol; 2004 Jun; 14(3):281-6; discussion 285-6. PubMed ID: 15373167
[TBL] [Abstract][Full Text] [Related]
28. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
29. Risk of subsequent primary malignancies after dermatofibrosarcoma protuberans diagnosis: a national study.
Kurlander DE; Martires KJ; Chen Y; Barnholtz-Sloan JS; Bordeaux JS
J Am Acad Dermatol; 2013 May; 68(5):790-6. PubMed ID: 23261548
[TBL] [Abstract][Full Text] [Related]
30. Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis.
Gandaglia G; Becker A; Trinh QD; Abdollah F; Schiffmann J; Roghmann F; Tian Z; Montorsi F; Briganti A; Karakiewicz PI; Sun M
Eur J Surg Oncol; 2014 Jan; 40(1):103-12. PubMed ID: 24099755
[TBL] [Abstract][Full Text] [Related]
31. Surveillance in stage I testicular seminoma.
Chung P; Warde P
Urol Oncol; 2006; 24(1):75-9. PubMed ID: 16414499
[TBL] [Abstract][Full Text] [Related]
32. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men.
Fosså SD; Chen J; Schonfeld SJ; McGlynn KA; McMaster ML; Gail MH; Travis LB
J Natl Cancer Inst; 2005 Jul; 97(14):1056-66. PubMed ID: 16030303
[TBL] [Abstract][Full Text] [Related]
33. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
Bhojani N; Capitanio U; Suardi N; Jeldres C; Isbarn H; Shariat SF; Graefen M; Arjane P; Duclos A; Lattouf JB; Saad F; Valiquette L; Montorsi F; Perrotte P; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):342-8. PubMed ID: 20117287
[TBL] [Abstract][Full Text] [Related]
34. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
Abdel-Wahab M; Reis IM; Hamilton K
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
[TBL] [Abstract][Full Text] [Related]
35. Second malignancies following pure seminoma.
Rüther U; Dieckmann KP; Bussar-Maatz R; Eisenberger F
Oncology; 2000; 58(1):75-82. PubMed ID: 10644944
[TBL] [Abstract][Full Text] [Related]
36. [Second malignancies after radiotherapy for testicular seminoma: 2 cases].
Servagi-Vernat S; Créhange G; Lorchel F; Bontemps P; Bosset JF
Cancer Radiother; 2006 May; 10(3):145-7. PubMed ID: 16517197
[TBL] [Abstract][Full Text] [Related]
37. Management of Stage II testicular seminoma over a period of 40 years.
Detti B; Livi L; Scoccianti S; Gacci M; Lapini A; Cai T; Meattini I; Mileo AM; Iannalfi A; Bruni A; Biti G
Urol Oncol; 2009; 27(5):534-8. PubMed ID: 18848787
[TBL] [Abstract][Full Text] [Related]
38. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
[TBL] [Abstract][Full Text] [Related]
39. [Increased incidence of sarcoma in patients treated for seminoma].
Jacobsen GK; Mellemgaard A; Engelholm SA; Møller H
Ugeskr Laeger; 1994 Feb; 156(6):809-12. PubMed ID: 8016985
[TBL] [Abstract][Full Text] [Related]
40. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.
Shah BK; Khanal A
Anticancer Res; 2015 Jun; 35(6):3437-40. PubMed ID: 26026107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
